Pharmacokinetic drug interactions between ondansetron and tamoxifen in female sprague-dawley rats with DMBA-induced mammary tumor

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 521-528

  Yang, Si Hyung ^a   Suh, Jung Hwa ^a   Lee, Myung Gull ^b   Kim, So Hee ^c  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ajou University   (South Korea)

Author keywords

CYP2D; CYP3A1 2; DMBA rats; Hepatic and intestinal; Ondansetron; Pharmacokinetic interaction; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D; DIMETHYLBENZ[A]ANTHRACENE; ONDANSETRON; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; LIVER METABOLISM; LIVER MICROSOME METABOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANIMALS; ANTIEMETICS; AREA UNDER CURVE; CARCINOGENS; DRUG INTERACTIONS; FEMALE; INFUSIONS, INTRAVENOUS; MAMMARY NEOPLASMS, EXPERIMENTAL; ONDANSETRON; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84875890876     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jordan VC, Gapstur S and Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93(19): 1449-1457, 2001.
2. Boocock DJ, Maggs JL, White IN and Park BK: Alphahydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: Identification and quantification in vivo and in vitro. Carcinogenesis 20(1): 153-160, 1999.
3. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C and Berthou F: Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41(12): 1911-1919, 1991.
4. Crewe HK, Ellis SW, Lennard MS and Tucker GT: Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53(2): 171-178, 1997.
5. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A and Kupfer D: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21(4): 645-656, 1993.
6. Yang SH, Suh JH and Lee MG: Pharmacokinetic interaction between tamoxifen and ondansetron in rats: non-competitive (hepatic) and competitive (intestinal) inhibition of tamoxifen metabolism by ondansetron via CYP2D subfamily and 3A1/2. Cancer Chemother Pharmacol 65(3): 407-418, 2010.
7. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P and Tynes R: The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22(2): 269-274, 1994.
8. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR and Tarbit MH: Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23(11): 1225-1230, 1995.
9. Yang SH and Lee MG: Effects of CYP inducers and inhibitors on the ondansetron pharmacokinetics in rats: Involvement of CYP2D subfamily and 3A1/2 for the ondansetron metabolism. J Pharm Pharmacol 60(7): 853-861, 2008.
10. Yang SH and Lee MG: Dose-independent pharmacokinetics of ondansetron after intravenous and oral administration to rats: Contribution of hepatic and intestinal first-pass effects to low bioavailability. Biopharm Drug Dispos 29(7): 414-426, 2008.
11. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ and Jones RB: Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 24(1): 1-4, 1999.
12. Gilbert CJ, Petros WP, Vredenburgh J, Hussein A, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry D, McKinstry C and Peters WP: Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42(6): 497-503, 1998.
13. Li J, Gödecke T, Chen SN, Imai A, Lankin DC, Farnsworth NR, Pauli GF, van Breemen RB and Nikolić D: In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica 41(12): 1021-1030, 2011.
14. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR and Tarbit MH: Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23(11): 1225-1230, 1995.
15. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P and Tynes R: The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22(2): 269-274, 1994.
16. Lewis DFV: P450 substrate, specificity and metabolism. In: Cytochrome P450. Structure, Function and Metabolism. Taylor and Francis, Bristol, PA, p. 123, 1996.
17. Russo J and Russo IH: Atlas and histologic classification of tumors of rat mammary gland. J Mamm Gland Biol Neoplasia 5(2): 187-200, 2000.
18. Yang SH, Lee JH, Lee DY, Lee MG. Lyuk KC and Kim SH: Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. Arch Pharm Res 34(10): 1729-1734, 2011.
19. Hamdy SM, Latif AK, Drees EA and Soliman SM: Prevention of rat breast cancer by genistin and selenium. Toxicol Ind Health 28(8): 746-457, 2012
20. Russo J and Russo IH: Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39(1): 7-20, 1996.
21. Lee JH and Lee MG: Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25(8): 1915-1924, 2008.
22. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
23. Duggleby RG: Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 249: 61-90, 1995.
24. Kim SH, Choi YM and Lee MG: Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21(1): 1-17, 1993.
25. Lee DY, Chung HJ, Choi YH, Lee U, Kim SH, Lee I and MG Lee: Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. Eur J Pharm Sci 38(5): 465-471, 2009.
26. Chiou WL: Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6(6): 539-546, 1978.
27. Gibaldi M and Perrier D: Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, 1982.
28. Wilkinson GR and Shand DG: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18(4): 377-390, 1975.
29. Sakaeda T, Fukumura K, Takahashi K, Matsumura S, Matsuura E and Hirano K: Blood flow rate in normal and tumor-bearing rats in conscious state, under urethane anesthesia, and during systemic hypothermia. J Drug Target 6(4): 261-272, 1998.
30. Yang SH, Yang KH and Lee MG: Gender differences in ondansetron pharmacokinetics in rats. Biopharm Drug Dispos 29(7): 406-413, 2008.
31. Yang SH, Choi HG, Lim S-J, Lee MG and Kim SH: Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz [a]anthracene (DMBA)-induced mammary tumors in female Sprague-Dawley rats. Oncol Rep (E-pub ahead, in press).
32. Aiba T, Takehara Y, Okuno M and Hashimoto Y: Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res 20(5): 745-748, 2003.